Compared to PD-1/-L1 inhibitor monotherapy, relative risk ratios (RRRs) for any grade and high grade rash developed during PD-1/-L1 inhibitor treatment combined with chemotherapy were not significantly increased (RRR for any grade pruritus was 0.30 (95% CI 0.21-0.42, p < 0.00001), RRR for any grade rash was 0.84 (95% CI 0.61-1.15, p = 0.28), RRR for high grade rash was 1.43 (95% CI 0.46-4.40, p = 0.54). The gene discussed is PDCD1; the disease is Pruritus.